• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Tanimoto Azusa  谷本 梓

ORCIDConnect your ORCID iD *help
… Alternative Names

谷本 梓  タニモト アズサ

Less
Researcher Number 90776444
Other IDs
Affiliation (Current) 2025: 金沢大学, がん進展制御研究所, 助教
Affiliation (based on the past Project Information) *help 2023: 金沢大学, がん進展制御研究所, 助教
2018 – 2020: 金沢大学, がん進展制御研究所, 助教
Review Section/Research Field
Principal Investigator
Basic Section 53030:Respiratory medicine-related
Keywords
Principal Investigator
FOXK1 / 肺癌 / TNIK / CCL2 / 小細胞肺がん / 薬剤耐性 / 小細胞肺癌 / CCR2 / SCLC / PUMA … More / 分子標的薬 / ALK融合遺伝子 / ALK阻害薬 / 自然耐性 / ALK融合遺伝子陽性肺癌 / アポトーシス / p53 / Proteasome / Noxa / Mcl-1 / ALK Less
  • Research Projects

    (3 results)
  • Research Products

    (5 results)
  • Co-Researchers

    (1 People)
  •  Novel combination immunotherapy targeting the chemokine network in small cell lung cancer.Principal Investigator

    • Principal Investigator
      谷本 梓
    • Project Period (FY)
      2023 – 2025
    • Research Category
      Fund for the Promotion of Joint International Research (Fostering Joint International Research)
    • Review Section
      Basic Section 53030:Respiratory medicine-related
    • Research Institution
      Kanazawa University
  •  治療抵抗性小細胞肺がんにおけるケモカインネットワークを標的とした新規治療の開発Principal Investigator

    • Principal Investigator
      谷本 梓
    • Project Period (FY)
      2020
    • Research Category
      Grant-in-Aid for Early-Career Scientists
    • Review Section
      Basic Section 53030:Respiratory medicine-related
    • Research Institution
      Kanazawa University
  •  Elucidation of the mechanism of resistance to apoptosis in ALK rearranged NSCLCPrincipal Investigator

    • Principal Investigator
      Tanimoto Azusa
    • Project Period (FY)
      2018 – 2020
    • Research Category
      Grant-in-Aid for Early-Career Scientists
    • Review Section
      Basic Section 53030:Respiratory medicine-related
    • Research Institution
      Kanazawa University

All 2020 2019

All Journal Article Presentation

  • [Journal Article] Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression2020

    • Author(s)
      Tanimoto Azusa、Matsumoto Shingo、Takeuchi Shinji、Arai Sachiko、Fukuda Koji、Nishiyama Akihiro、Yoh Kiyotaka、Ikeda Takaya、Furuya Naoki、Nishino Kazumi、Ohe Yuichiro、Goto Koichi、Yano Seiji
    • Journal Title

      Clinical Cancer Research

      Volume: 27 Issue: 5 Pages: 1410-1420

    • DOI

      10.1158/1078-0432.ccr-20-2853

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-20K08516, KAKENHI-PROJECT-19H03665, KAKENHI-PROJECT-18K15922
  • [Presentation] ALK融合遺伝子陽性肺癌におけるp53の機能低下に起因するALK阻害薬耐性の新規克服治療の開発2020

    • Author(s)
      谷本 梓
    • Organizer
      第86回日本呼吸器学会北陸地方会
    • Data Source
      KAKENHI-PROJECT-18K15922
  • [Presentation] 分子標的薬の自然耐性に着目した基礎研究と臨床応用への試み2019

    • Author(s)
      谷本 梓
    • Organizer
      第13回日本緩和医療薬学会年会
    • Invited
    • Data Source
      KAKENHI-PROJECT-18K15922
  • [Presentation] Proteasome inhibitor overcomes ALK-TKI resistance by p53 inactivation through Noxaexpression in EML4-ALK NSCLC2019

    • Author(s)
      谷本 梓
    • Organizer
      第17回日本臨床腫瘍学会学術集会
    • Data Source
      KAKENHI-PROJECT-18K15922
  • [Presentation] ALK 融合遺伝子陽性肺癌においてp53 の機能低下がもたらすALK-TKI 自然耐性の克服2019

    • Author(s)
      谷本 梓
    • Organizer
      第60回日本肺癌学会学術集会
    • Data Source
      KAKENHI-PROJECT-18K15922
  • 1.  TAKEUCHI Shinji
    # of Collaborated Projects: 0 results
    # of Collaborated Products: 1 results

URL: 

Are you sure that you want to link your ORCID iD to your KAKEN Researcher profile?
* This action can be performed only by the researcher himself/herself who is listed on the KAKEN Researcher’s page. Are you sure that this KAKEN Researcher’s page is your page?

この研究者とORCID iDの連携を行いますか?
※ この処理は、研究者本人だけが実行できます。

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi